Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study

Autor: Sandrine Faivre, Patricia Niccoli, Aaron I. Vinik, Peter Metrakos, C. Lombard-Bohas, D. Smith, Y.-J. Bang, K.J. Ishak, Pascal Hammel, Shem Patyna, Jean-Luc Raoul, E. Raymond, Jin-Shyr Chen, E. Van Cutsem, Ivan Borbath, Daniel Castellano, D. Lu, Juan W. Valle, J.F. Seitz, Philippe Ruszniewski, Sang Hyub Lee

Publikováno v: Faivre, S, Niccoli, P, Castellano, D, Valle, J W, Hammel, P, Raoul, J-L, Vinik, A, Van Cutsem, E, Bang, Y-J, Lee, S-H, Borbath, I, Lombard-Bohas, C, Metrakos, P, Smith, D, Chen, J-S, Ruszniewski, P, Seitz, J-F, Patyna, S, Lu, D R, Ishak, K J & Raymond, E 2017, ' Sunitinib in Pancreatic Neuroendocrine Tumors : Updated Progression-Free Survival and Final Overall Survival From a Phase III Randomized Study ', Annals of Oncology . https://doi.org/10.1093/annonc/mdw561

BACKGROUND: In a phase III trial in patients with advanced, well-differentiated, progressive pancreatic neuroendocrine tumors, sunitinib 37.5 mg/day improved investigator-assessed progression-free survival (PFS) versus placebo (11.4 vs. 5.5 months; H

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa1c75abe5aba1d51efbc55f02d519c7
https://doi.org/10.1093/annonc/mdw561

Pharmacokinetics, Distribution, and Metabolism of [14C]Sunitinib in Rats, Monkeys, and Humans

Autor: Geoffrey Peng, Shem Patyna, Bill Speed, Hai-Zhi Bu, William F. Pool, Ellen Y. Wu, Carlo L. Bello, Ping Kang

Publikováno v: Drug Metabolism and Disposition. 40:539-555

Sunitinib is an oral multitargeted tyrosine kinase inhibitor approved for the treatment of advanced renal cell carcinoma, imatinib-refractory gastrointestinal stromal tumor, and advanced pancreatic neuroendocrine tumors. The current studies were cond

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e48112042a2c6e670beb20c5ac898183
https://doi.org/10.1124/dmd.111.042853

Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species

Autor: Ellen Y. Wu, Qingling Zhang, Juthamas Sukbuntherng, William Speed, Joshua Ö. Haznedar, Shem Patyna, Geoffrey Peng, David J. Sweeny, Carlo L. Bello, Xiaoming Yu, Lida Antonian

Publikováno v: Cancer Chemotherapy and Pharmacology. 64:691-706

The purpose of these extensive non-clinical studies was to assess pharmacokinetics and dispositional properties of sunitinib and its primary active metabolite (SU12662). Sunitinib was administered in single and repeat oral doses in mice, rats, and mo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::984caf182fb27ef2932580d6dec97de9
https://doi.org/10.1007/s00280-008-0917-1

Sunitinib (SU) in patients with advanced, progressive pancreatic neuroendocrine tumors (pNET): Final overall survival (OS) results from a phase III randomized study including adjustment for crossover

Autor: Xin Huang, Jen-Shi Chen, Denis Smith, Ivan Borbath, Peter Metrakos, Eric Raymond, Jean Francois Seitz, Daniel Castellano, Se-Hoon Lee, Yung-Jue Bang, Jack Ishak, Sandrine Faivre, Catherine Lombard Bohas, Pascal Hammel, Shem Patyna, Juan W. Valle, Philippe Ruszniewski, Patricia Niccoli, Jean-Luc Raoul, Aaron I. Vinik

Publikováno v: Journal of Clinical Oncology. 34:309-309

309 Background: In 2010, the pivotal double blind Phase III study met its primary endpoint with a median progression-free survival (PFS) of 11.4 months (mo) for sunitinib vs. 5.5 mo for placebo (PBO) (HR=0.42; 95% CI 0.26-0.66; P

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0895c03e6945f4c6904e7d1b5e1c7da0
https://doi.org/10.1200/jco.2016.34.4_suppl.309

The discovery and development of SU14813, a next-generation multitargeted tyrosine kinase inhibitor for the treatment of human malignancies

Autor: Dana D. Hu-Lowe, Nicoletta Brega, Shem Patyna

Publikováno v: Molecular cancer therapeutics. 10(11)

Commentary on: [Shem Patyna, A. Douglas Laird, Dirk B. Mendel, Anne-Marie O'Farrell, Chris Liang, Huiping Guan, Tomas Vojkovsky, Stefan Vasile, Xueyan Wang, Jeffrey Chen, Maren Grazzini, Cheng Y. Yang, Joshua O. Haznedar, Juthamas Sukbuntherng, Wei-Z

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa5ee96d6896ecd9f96069bcae570b1e
https://pubmed.ncbi.nlm.nih.gov/16891463